Brentuximab Vedotin: Uses, Cost and Side Effects

Only lymphomas — and only those carrying the CD30 protein. Classical Hodgkin lymphoma is the main one. It is also approved in systemic anaplastic large cell lymphoma and other CD30-expressing peripheral T-cell lymphomas, in two skin lymphomas, and in relapsed large B-cell lymphoma. It has no role in solid tumours.

The biopsy decides before anything else does. CD30 is checked by immunohistochemistry on the tumour tissue. Classical Hodgkin lymphoma carries it almost by definition. In peripheral T-cell lymphoma the expression varies from case to case, and the pathology report has to state it.

Indian regulatory position, as of August 2026. Takeda has stated publicly that it is authorised by the Drug Controller General of India to import, sell and distribute Adcetris in India. The company made that statement publicly in September 2023, in response to a CDSCO advisory about falsified vials. Takeda Pharmaceuticals India Pvt Ltd is listed as the Indian marketer of the product. The exact wording of the Indian approved indications sits in the approved product information the treating hospital holds; the table below sets out the internationally approved set, which is what most guideline discussion refers to.

Because it is two medicines chemically joined into one. A monoclonal antibody targets CD30 on the lymphoma cell. A chemotherapy agent, monomethyl auristatin E, is attached to that antibody by a linker. The antibody carries the payload inside the cell, the linker is cut, and the chemotherapy is released mainly where the target protein is.

Is this immunotherapy? Indian hospital billing and insurance paperwork often file brentuximab vedotin under immunotherapy, because the targeting half of it is an antibody. That is a fair description of the parts, and it is one of the reasons patients meet the word without ever being told what class the medicine really belongs to. It is not a checkpoint inhibitor. It does not release a brake on T cells the way pembrolizumab or nivolumab do.

The distinction is practical, not academic. It changes which side effects the team watches for. A checkpoint inhibitor is watched for immune-related inflammation of the gut, lungs, thyroid and liver. An antibody-drug conjugate is watched for the effects of the chemotherapy it carries — low blood counts, nausea, hair loss — plus the nerve damage this particular payload causes.

Peripheral neuropathy — numbness, tingling, burning or weakness that starts in the toes and fingertips. It is the most common reason the dose is reduced or the medicine is stopped. It builds up with the total dose received rather than arriving all at once. In most people it improves after treatment ends, though not always completely.

This is the part of the conversation that matters most for a young adult. Classical Hodgkin lymphoma is largely a young person’s cancer in India, and the person being asked to accept a nerve side effect is often someone who types for a living, rides a two-wheeler, plays a sport or is halfway through a degree. The trade-off is real and it is worth naming out loud before the first cycle.

Say it early, not at the end. Neuropathy is graded on what the patient reports, so an unreported symptom is an unmanaged one. Mentioning tingling at cycle two gives the team the option of a dose reduction. Mentioning it at cycle six, after months of accumulation, leaves fewer options. There is no medicine that reverses it once it has built up; the dose change is the tool.

One symptom set that is not neuropathy and is not for home management. New confusion, memory loss, changes in vision or speech, or new weakness down one side of the body. Progressive multifocal leukoencephalopathy, a rare brain infection, carries a boxed warning on this medicine. Anyone with those symptoms should go to the hospital treating them the same day and say which medicine they are on when they arrive.

Indian pharmacy listings put the maximum retail price of a single 50 mg Adcetris vial at about ₹2.09 lakh — indicative, as of August 2026. Discounted online listings sit nearer ₹1.7 lakh. A vial price is not a dose price. At 1.8 mg per kg every three weeks, an adult of about 60 kg needs three vials for one dose.

Three things move the number more than the brand does. Body weight, because the dose is calculated per kilogram and vials are supplied in fixed 50 mg strengths. The number of doses planned, which is fixed in the frontline and consolidation settings and open-ended in some relapsed settings. And whether the estimate separates the medicine from day-care, monitoring and consultation charges — an itemised estimate makes every other question answerable.

Vial wastage is a real line item. These are single-dose vials with no preservative, so a part-used vial is not carried over to the next patient or the next cycle. A 108 mg dose consumes three 50 mg vials and 42 mg is discarded. Asking how the hospital handles vial sharing and wastage is a fair question, and the answer should be the same in writing as it is in conversation.

Anyone whose lymphoma is not CD30-positive, and anyone whose cancer is not a lymphoma. Brentuximab vedotin recognises one protein. Without that protein on the tumour there is nothing for it to bind to, and no price makes it appropriate. The pathology report decides eligibility long before the cost conversation starts.

• Not for solid tumours. Breast, lung, oral, colorectal and prostate cancer are outside this medicine’s scope entirely. It is not a general-purpose immunotherapy and it is not an alternative to a checkpoint inhibitor.
• Not for CD30-negative lymphoma. If immunohistochemistry does not show CD30 on the tumour cells, the medicine has no target. In peripheral T-cell lymphoma this has to be checked case by case rather than assumed.
• Never together with bleomycin. The combination is contraindicated because of pulmonary toxicity. This is why the frontline Hodgkin lymphoma regimen that includes brentuximab vedotin is AVD and not ABVD — the bleomycin is deliberately left out.
• Not straightforward where nerve damage already exists. Long-standing diabetic neuropathy, or neuropathy left over from earlier vinca-alkaloid or platinum chemotherapy, changes the risk calculation. That is a judgement for the treating team, made with a baseline examination, not a decision to take from a web page.
• Not used unchanged in moderate or severe liver impairment. The approved product information restricts use and requires specialist assessment, because the payload is cleared through the liver.
• Not in pregnancy. It can harm a developing baby. Contraception is advised during treatment and for a period afterwards, and men are advised not to father a child during that period; the interval is set by the treating team.
• Not a substitute for the rest of the plan. It is given with chemotherapy, or after a stem cell transplant, not instead of either. Choosing it in place of a recommended treatment is not a cost saving.

It is also not interchangeable with other antibody-drug conjugates. Polatuzumab vedotin targets CD79b, trastuzumab deruxtecan targets HER2, and enfortumab vedotin targets Nectin-4. They share a payload family and nothing else that matters clinically. Confirming which molecule a prescription actually names is worth doing before any cost planning begins.

No Indian biosimilar or similar biologic of brentuximab vedotin is marketed here as of August 2026. It remains a patented, imported product with a single supplier in India. Antibody-drug conjugates are also genuinely harder to manufacture than plain antibodies, because the payload and the chemical linker have to be attached to a consistent standard.

India has a well-worn pattern for antibody prices, and this molecule is at the wrong end of it. Rituximab and trastuzumab both lost exclusivity here years ago, several approved similar biologics compete on price, and the cost of a course fell steeply as a result. That is what an Indian biosimilar market looks like once it matures. None of it has happened for brentuximab vedotin, and nothing suggests it is close.

Waiting for a price fall is therefore not a plan. Classical Hodgkin lymphoma in a young adult is treated on a schedule, and postponing treatment to chase a future price is a clinical decision with clinical consequences. The more useful moves are the ordinary ones: confirm the number of doses planned, check what an insurer will actually settle, and ask the hospital about the manufacturer’s patient-assistance programme in writing.

Two neighbouring molecules show how differently the same class can be priced and supplied in India. Daratumumab: Uses, Cost and Side Effects in Myeloma covers an antibody in a blood cancer where the Indian supply picture has changed, and Blinatumomab: The Bispecific Antibody for Leukaemia covers an antibody built to a different design again, with a different administration burden.

This is a real question for this particular medicine, not a general worry. In September 2023 CDSCO issued an advisory about falsified versions of Adcetris 50 mg, following a World Health Organization alert that identified falsified vials in four countries, including India. At least eight falsified batch numbers were listed in circulation.

The WHO reported that the falsified products were moving mainly through unregulated supply chains, largely online, and had been identified in both regulated and illicit chains, sometimes reaching patient level. CDSCO asked doctors to prescribe carefully and to educate patients about reporting adverse drug reactions, asked patients to obtain medical products only from authorised sources with a proper purchase invoice, and directed state drug controllers to keep strict watch over the movement, sale, distribution and stock of the product, drawing samples where needed. Takeda responded that it is authorised by the Drug Controller General of India to import, sell and distribute Adcetris in India and recommended procurement only from its authorised distribution sources.

• Source it through the treating hospital’s pharmacy or a manufacturer-authorised distributor. Keep the invoice. A cold-chain biologic bought from an online marketplace listing or an informal courier arrangement cannot be verified afterwards.
• Check the cold chain. The vial is stored at 2 to 8 degrees Celsius and is not frozen. Ask how it was transported and how long it was out of refrigeration.
• Photograph the carton before it is discarded. Batch number and expiry date belong in the patient file. If a batch is flagged later, that record is what makes the check possible.
• Report anything unexpected. An unusual reaction, or no expected effect at all, is worth raising with the treating team as a possible adverse drug reaction rather than being written off.

The wider picture, and how to run the same checks on any vial, is set out in How to Verify an Immunotherapy Vial Is Genuine and Counterfeit Immunotherapy Drugs in India.

Blood counts before every dose, and a short list of specific warnings. Neutropenia is common and can be severe. Infusion reactions happen during or shortly after the drip. Liver injury, pancreatitis, high blood sugar and tumour lysis syndrome are all recognised. Progressive multifocal leukoencephalopathy is rare and carries a boxed warning.

Treatment is given as a day-care infusion, so a treatment day does not usually require admission. Reactions during the drip itself are common enough across this whole class of medicines to be worth reading about in advance — Infusion Reactions With Antibody Medicines: What to Expect sets out what is routine, what is not, and what the day-care team is watching while the drip runs.

• Daratumumab: Uses, Cost and Side Effects in Myeloma — an antibody in a different blood cancer, with a different Indian supply story.
• Blinatumomab: The Bispecific Antibody for Leukaemia — a third antibody design again, and what it asks of a patient.
• Infusion Reactions With Antibody Medicines: What to Expect — what happens during the drip, and what is not routine.
• Immunotherapy Medicines Explained — the index of checkpoint inhibitors, antibodies and molecule-by-molecule Indian cost pages.
• Immunotherapy at CION — what this family of treatments does, who it suits, and who it does not.

Editorial information about a named medicine — not an offer, a price list, or a recommendation to use it, and no comparative quality claim between manufacturers. All pricing, regulatory, dosing and safety statements are indicative and dated to August 2026, drawn from published Indian pharmacy listings, CDSCO and World Health Organization advisories, the manufacturer’s published indication list and approved product information. Whether brentuximab vedotin applies to a particular lymphoma is a decision for the treating oncologist, on the basis of a CD30 result on the biopsy and the full clinical picture.